



DOCKET NO.: JJPR-0050 (ORT 1060CON)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

**Alain Luxembourg**

**Application No.: 10/785,472**

**Filing Date: February 23, 2004**

**For: PURIFICATION OF ANTIGEN-SPECIFIC T CELLS**

**Confirmation No.: 1342**

**Group Art Unit: 1644**

**Examiner: Francois P. Vandervegt**

DATE OF DEPOSIT: February 17, 2006

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: Janet E. Reed, Ph.D.  
REGISTRATION NO.: 36,252

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ A Copy of reference number 1 listed on the attached Form PTO-1449 is enclosed herewith.

- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.


**DOCKET NO.: JJPR-0050 (ORT 1060CON)- 3 -**

**PATENT**

There are no listed references which are not in the English language.


Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: February 17, 2006

  
\_\_\_\_\_  
Janet E. Reed, Ph.D.  
Registration No. 36,252

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

© 2006 WW



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. JJPR-0050		Application No. 10/785,472	
	Applicant Alain T. Luxembourg, et al.			
	Filing Date February 23, 2004		Group 1644	
	Confirmation No. 1342			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>				
	1	Tallquist, M. D., et al., "Alloreactive 2C T Cells Recognize a Self Peptide in the Context of the Mutant K <sup>bm3</sup> Molecule," <i>J Immunol.</i> , 1995, 155(5), 2419-2426		
	2			
	3			
	4			
	5			
	6			
	7			
	8			
	9			
	10			
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>		